Current Au NP preparations are limited by phase transfer, as surface modification causes difficulty in transferring Au NPs to a designated solvent.
All arylation reactions were conducted at 2 mmol scale under argon for 5 6 h, then addition of oxidants (2.2 mmol) or open to air aCopper salts (0.1 eq)., LiN(SiMe3)2 (2.0 eq)., designated solvent, 80 °C bPd2 dba 3 (0.05 eq)., Ph3P (0.2 eq)., LiN(SiMe3)2 (2.0 eq)., toluene, 80 °C.
The liquid in a solution is customarily designated the solvent, and the substance added is called the solute.
The system in which the potential gelator could not be dissolved even at the boiling point of the solvent was designated as an insoluble system (I).
With respect to the step of reconstitution, 0.1% formic acid was designated as the reconstitution solvent vs. 6.5 mM ammonium bicarbonate, based on the comparable number of metabolite peaks detected in both solvents, and yet the signal detected in the former was higher.
Ionic liquids (ILs) are designated as desirable 'green' solvents due to their low volatility, excellent dissolution ability, and high thermochemical stability, which have currently attracted widespread attention [ 10, 13, 14].
Again a 4 ns CMD simulation was firstly performed in order to make the imatinib-Abl equilibrated in the solvent at the designated temperature.
Drug-treated wells were compared with solvent control wells, and the concentration of drug that resulted in 50% of the cell growth of the solvent control was designated as the GI50 concentration, calculated using Graphpad PRISM 5 (Graphpad Software, La Jolla, CA, USA).
The Asc∙ signal of a solvent control group was arbitrarily designated 100% and was inhibited by AA861 (1–10 μM) dose dependently (10 μM = 25.7%, P < 0.001, Figure 5(b)).
The Asc∙ signal of a solvent control group was arbitrarily designated 100% and was dose dependently inhibited by DPI (3 μM = 17.7%, P < 0.05; 10 μM = 23.8%, P < 0.001, Figure 3(a)).
In addition, the Asc∙ signal of the solvent control group was arbitrarily designated 100% and was inhibited by quinacrine (2.5 10 μM), a phospholipidase A2 (PLA2) inhibitor, dose dependently (5 μM = 20.9%, P < 0.001; 10 μM = 26.2%, P < 0.001, Figure 4(b)).
